NCT00585650View on ClinicalTrials.gov

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Psoriasis
Interventions
BIOLOGICAL

Etanercept

Subcutaneous injections 50 mg Etanercept will occur twice weekly over a 12-week treatment period.

OTHER

Placebo injections

Placebo injections twice weekly for 12 weeks.

Trial Locations (3)

27157

Wake Forest University School of Medicine, Winston-Salem

92697

UC Irvine Dermatology Clinical Research Center, Irvine

98101

Dermatology Associates, PLLC, Seattle

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

University of California, Irvine

OTHER